by Charles D. Cash, JD, LLM Mr. Cash is Associate Director of Risk Management at Professional Risk Management Services (PRMS). FUNDING: No funding was provided for the preparation of this
Innov Clin Neurosci. 2025;22(1–3):11–13. Dear Editor: I read with interest Lawrence’s article about a 33-year-old male patient with migraine with aura who self-experimented with psilocybin for his migraine attacks, which
Innov Clin Neurosci. 2025;22(1–3):11–13. Dear Editor: Thank you for your interest in this case report1 and for your insightful comments. I appreciate the thoroughness of your feedback and concur with
Innov Clin Neurosci. 2025;22(1–3):11–13. Dear Editor: Emerging data on sex differences in the efficacy and tolerability of antipsychotics in patients with schizophrenia are not taken into account in current guidelines,
by Eirini Beneki, MSc, MD, PhD(c); Kyriakos Dimitriadis, MD, PhD; Elias Zintzaras, MD, PhD; Panagiotis Kostakis, MD, PhD(c); Constantina Aggeli, MD, PhD; and Konstantinos Tsioufis, MD, PhD Drs. Beneki, Dimitriadis,
